Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benazepril: a new ACE inhibitor

J Bell

    ANNA Journal
    |April 1, 1993
    PubMed
    Summary

    Benazepril, an ACE inhibitor, is safe for patients with kidney or liver disease and shows consistent efficacy across age groups. Its convenient once-daily dosing and lack of drug interactions enhance patient adherence.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Lemierre's syndrome complicating pregnancy.

    Infectious diseases in obstetrics and gynecology·2007
    Same author

    Virtual vs. optical colonoscopy in symptomatic gastroenterology out-patients: the case for virtual imaging followed by targeted diagnostic or therapeutic colonoscopy.

    Alimentary pharmacology & therapeutics·2007
    Same author

    Acute ventricular and aortic thrombosis post chemotherapy.

    The British journal of radiology·2007
    Same author

    New system threatens UK clinical research.

    BMJ (Clinical research ed.)·2007
    Same author

    Ganglion cysts at the gastrocnemius origin: a series of ten cases.

    Skeletal radiology·2006
    Same author

    Subglottic cysts in children: a 10-year review.

    International journal of pediatric otorhinolaryngology·2006

    Area of Science:

    • Pharmacology
    • Nephrology
    • Geriatrics

    Background:

    • Benazepril is an angiotensin-converting enzyme (ACE) inhibitor.
    • ACE inhibitors are a class of drugs used to treat hypertension and heart failure.
    • Benazepril is considered safe for patients with renal and liver disease.

    Purpose of the Study:

    • To evaluate the safety and efficacy of benazepril in patients with renal and liver disease.
    • To compare the pharmacokinetics of benazepril in young patients versus elderly patients.
    • To assess potential drug interactions with commonly prescribed medications.

    Main Methods:

    • Statistical analysis of single and repeated 10 mg oral doses of benazepril.
    • Comparison of drug action between young and elderly patient groups.
    • Review of potential pharmacologic interactions with other drugs.

    Main Results:

    • Benazepril can be safely administered to patients with renal and liver disease.
    • No significant difference in benazepril's action was observed between young and elderly patients.
    • Benazepril demonstrated no clinically significant pharmacologic interactions with commonly used medications.

    Conclusions:

    • Benazepril is a safe and effective ACE inhibitor for diverse patient populations, including those with renal or liver impairment and across different age groups.
    • The convenient dosing schedule (once daily, with or without food) of benazepril improves patient compliance, particularly for those on multiple medications.
    • Benazepril offers a favorable safety profile due to its lack of significant drug interactions with common co-administered drugs.

    Related Experiment Videos